204 related articles for article (PubMed ID: 34170046)
1. Clinical and molecular data in cases of prenatal localized overgrowth disorder: major implication of genetic variants in PI3K-AKT-mTOR signaling pathway.
Bourgon N; Carmignac V; Sorlin A; Duffourd Y; Philippe C; Thauvin-Robinet C; Guibaud L; Faivre L; Vabres P; Kuentz P;
Ultrasound Obstet Gynecol; 2022 Apr; 59(4):532-542. PubMed ID: 34170046
[TBL] [Abstract][Full Text] [Related]
2. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
Pirozzi F; Berkseth M; Shear R; Gonzalez L; Timms AE; Sulc J; Pao E; Oyama N; Forzano F; Conti V; Guerrini R; Doherty ES; Saitta SC; Lockwood CM; Pritchard CC; Dobyns WB; Novotny E; Wright JNN; Saneto RP; Friedman S; Hauptman J; Ojemann J; Kapur RP; Mirzaa GM
Brain; 2022 Apr; 145(3):925-938. PubMed ID: 35355055
[TBL] [Abstract][Full Text] [Related]
3. Megalencephaly syndromes associated with mutations of core components of the PI3K-AKT-MTOR pathway: PIK3CA, PIK3R2, AKT3, and MTOR.
Dobyns WB; Mirzaa GM
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):582-590. PubMed ID: 31441589
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
[TBL] [Abstract][Full Text] [Related]
5. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
[TBL] [Abstract][Full Text] [Related]
6. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.
Negishi Y; Miya F; Hattori A; Johmura Y; Nakagawa M; Ando N; Hori I; Togawa T; Aoyama K; Ohashi K; Fukumura S; Mizuno S; Umemura A; Kishimoto Y; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Nakanishi M; Saitoh S
BMC Med Genet; 2017 Jan; 18(1):4. PubMed ID: 28086757
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
9. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
10. Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism.
Yeung KS; Tso WWY; Ip JJK; Mak CCY; Leung GKC; Tsang MHY; Ying D; Pei SLC; Lee SL; Yang W; Chung BH
Mol Autism; 2017; 8():66. PubMed ID: 29296277
[TBL] [Abstract][Full Text] [Related]
11. Polymicrogyria in association with hypoglycemia points to mutation in the mTOR pathway.
Stutterd C; McGillivray G; Stark Z; Messazos B; Cameron F; White S; ; Mirzaa G; Leventer R
Eur J Med Genet; 2018 Dec; 61(12):738-740. PubMed ID: 29883676
[TBL] [Abstract][Full Text] [Related]
12. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.
Mirzaa GM; Rivière JB; Dobyns WB
Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):122-30. PubMed ID: 23592320
[TBL] [Abstract][Full Text] [Related]
13. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.
Keppler-Noreuil KM; Parker VE; Darling TN; Martinez-Agosto JA
Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):402-421. PubMed ID: 27860216
[TBL] [Abstract][Full Text] [Related]
14. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
15. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes.
Rivière JB; Mirzaa GM; O'Roak BJ; Beddaoui M; Alcantara D; Conway RL; St-Onge J; Schwartzentruber JA; Gripp KW; Nikkel SM; Worthylake T; Sullivan CT; Ward TR; Butler HE; Kramer NA; Albrecht B; Armour CM; Armstrong L; Caluseriu O; Cytrynbaum C; Drolet BA; Innes AM; Lauzon JL; Lin AE; Mancini GM; Meschino WS; Reggin JD; Saggar AK; Lerman-Sagie T; Uyanik G; Weksberg R; Zirn B; Beaulieu CL; ; Majewski J; Bulman DE; O'Driscoll M; Shendure J; Graham JM; Boycott KM; Dobyns WB
Nat Genet; 2012 Jun; 44(8):934-40. PubMed ID: 22729224
[TBL] [Abstract][Full Text] [Related]
16. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.
Jansen LA; Mirzaa GM; Ishak GE; O'Roak BJ; Hiatt JB; Roden WH; Gunter SA; Christian SL; Collins S; Adams C; Rivière JB; St-Onge J; Ojemann JG; Shendure J; Hevner RF; Dobyns WB
Brain; 2015 Jun; 138(Pt 6):1613-28. PubMed ID: 25722288
[TBL] [Abstract][Full Text] [Related]
17. Hypoglycemia due to PI3K/AKT/mTOR signaling pathway defects: two novel cases and review of the literature.
Maines E; Franceschi R; Martinelli D; Soli F; Lepri FR; Piccoli G; Soffiati M
Hormones (Athens); 2021 Dec; 20(4):623-640. PubMed ID: 33876391
[TBL] [Abstract][Full Text] [Related]
18. The ClinGen Brain Malformation Variant Curation Expert Panel: Rules for somatic variants in AKT3, MTOR, PIK3CA, and PIK3R2.
Lai A; Soucy A; El Achkar CM; Barkovich AJ; Cao Y; DiStefano M; Evenson M; Guerrini R; Knight D; Lee YS; Mefford HC; Miller DT; Mirzaa G; Mochida G; Rodan LH; Patel M; Smith L; Spencer S; Walsh CA; Yang E; Yuskaitis CJ; Yu T; Poduri A;
Genet Med; 2022 Nov; 24(11):2240-2248. PubMed ID: 35997716
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the sonic hedgehog pathway cause macrocephaly-associated conditions due to crosstalk to the PI3K/AKT/mTOR pathway.
Klein SD; Nguyen DC; Bhakta V; Wong D; Chang VY; Davidson TB; Martinez-Agosto JA
Am J Med Genet A; 2019 Dec; 179(12):2517-2531. PubMed ID: 31639285
[TBL] [Abstract][Full Text] [Related]
20. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.
Lee JH; Huynh M; Silhavy JL; Kim S; Dixon-Salazar T; Heiberg A; Scott E; Bafna V; Hill KJ; Collazo A; Funari V; Russ C; Gabriel SB; Mathern GW; Gleeson JG
Nat Genet; 2012 Jun; 44(8):941-5. PubMed ID: 22729223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
